Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06544109
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
None
First Post:
2024-08-06
Brief Title:
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Venetoclax for Prevention of Differentiation Syndrom DS in Acute Promyelocytic Leukemia APL Patients An Open-lable Single-arm Multicenter Phase Ⅱ Clinical Trail
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Ven APL
Brief Summary:
This study is to assess the efficacy and safety of venetoclax for prevention of DS in APL patients undergoing ATRAATO induction regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None